- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04411225
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomly assigned in a 1:1 ratio to receive CBD or matching Placebo as an add-on to antipsychotic medication in an 8 week double blind trial. In this study, Cannabidiol Oral Solution (CBD) product will be used. This product is manufactured and supplied by GW Pharmaceuticals. The formulation is a 100 mg/mL solution. The CBD compound will be dosed at 1000mg/day administered in two divided doses. The dose of CBD was selected based on previous controlled trials that demonstrate the efficacy of CBD in patients with schizophrenia.
The maximum duration of the study from screening to follow up of outcomes and adverse events will be approximately 8 weeks. Participants will receive either the CBD or placebo within this eight.weeks and will also complete pre-treatment, midpoint (week 4) and post-treatment testing (week 8).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Kristin Cadenhead
- Phone Number: 619-543-6445
- Email: KCADENHEAD@UCSD.EDU
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Recruiting
- UC San Diego
-
Contact:
- Kristin Cadenhead, MD
- Phone Number: 619-543-6445
- Email: kcadenhead@health.ucsd.edu
-
Contact:
- Heline Mirzakhanian, PhD
- Phone Number: 619-543-7745
- Email: hmirzakhanian@health.ucsd.edu
-
San Diego, California, United States, 92093
- Recruiting
- University of California, San Diego
-
Contact:
- Tracy Alderman, PhD
- Phone Number: 619-543-7761
- Email: talderman@ucsd.edu
-
Principal Investigator:
- Kristin S Cadenhead, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- First episode psychosis (onset within the last 2 years) or attenuated psychosis syndrome (APS), stabilized with treatment for at least 8 weeks prior to initiating the trial consistent with the FDA-NIMH-MATRICS guidelines for clinical trial design for clinical enhancing drugs:
- Clinically stable and in a nonacute phase of their illness for at least 2 months, First episode psychosis participants will have been maintained on current antipsychotic for at least 6 weeks, with no change in antipsychotic dose for the previous 4 weeks while APS participants will be on the same treatment regimen (psychosocial or pharmacologic) for 4 weeks,
- Exhibit no more than moderate levels of positive symptoms (defined by ratings of ≤ 4) on PANSS items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory behavior), P5 (grandiosity), P6 (suspiciousness), and G8 (unusual thought content),
- No more than a minimal level of depressive symptoms as assessed by the Calgary Depression Scale for Schizophrenia (CDSS)
- Acceptable diagnoses will include APS, Psychosis NOS, Schizophreniform, Schizophrenia, and Schizoaffective per the Structured Clinical Interview for DSM-V.
Exclusion Criteria:
- Concomitant medical or neurological illness;
- Significant head injury;
- Current substance abuse or positive toxicology screen for drugs including THC and CBD as detected by urine and blood samples.
- Impaired intellectual functioning IQ<80; however those with an IQ i the 75-79 range will be include if WRAT reading > 85 suggesting higher premorbid IQ.
- High suicidal risk assessed by the The Columbia-Suicide Severity Rating Scale (C-SSRS)42
- Pregnant women and those who do not agree to avoid becoming pregnant
- Patients requiring treatment with Azelastine, Azelastine; Fluticasone, Dronabinol, Valproic Acid, or Divalproex Sodium
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabidiol Augmentation
The cannabidiol will be administered as an oral solution to be mixed in any fluid.
The formulation is 100 mg/ml.
It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
|
Both the active drug (cannabidiol) and placebo will be in oral solution.
Other Names:
|
Placebo Comparator: Placebo Augmentation
Placebo will appear identical to the cannabidiol solution
|
Both the active drug (cannabidiol) and placebo will be in oral solution.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Symptoms of Psychosis
Time Frame: Week 7
|
Psychotic symptoms will be assessed with The Positive and negative psychotic syndrome scale (PANSS).
This scale provides a summary score of all positive symptoms and all negative symptoms in participants who are already diagnosed with a psychotic disorder.
The total score ranges from 30 to 210 with a higher score representing more symptoms.
|
Week 7
|
Neurocognition
Time Frame: week 7
|
A Global Cognition Score will be assessed with Measurement and Treatment Research in Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) in all subjects.The Global Cognitive Score is a composite of the Z scores across the different cognitive domains in the MCCB.
The range of scores is -1 to +1.
Positive scores represent better cognitive functioning.
|
week 7
|
Prodromal Symptoms
Time Frame: Week 7
|
The Scale of Prodromal Symptoms (SOPS) is part of the Structured Interview for Prodromal Syndromes (SIPS) diagnostic interview.
This scale will be used to assess subsyndromal psychotic symptoms in participants who are diagnosed as Clinical High Risk for Psychosis.
Positive and Negative Symptoms will be assessed as summary scores of all positive or negative items The minimum score on the SOPS total is 0 and Maximum is 24.
A higher score represents more symptoms.
|
Week 7
|
General Symptoms
Time Frame: week 7
|
The Brief Psychiatric Rating Scale (BPRS) will be used as an assessment of overall symptom ratings with a total score in all subjects.
The minimum score is 24 and maximum is 168.
A higher score represents more symptoms.
|
week 7
|
Clinical Global Impression Scale (CGI-S)
Time Frame: Week 7
|
The CGI-S will provide a global psychopathology score for all subjects.
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.
A "1" is considered normal while a "7" is extremely ill.
|
Week 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral Biomarkers of Inflammation
Time Frame: week 7
|
Panel of chemokines and cytokines expressed as "Mean Concentration Value". The minimum and maximum value for each measure between 0 and 40,280. In general higher values represent greater immune activation. Cytokines: Interferon-gamma, Interleukin-1, Interleukin-6, Interleukin-10, Interleukin-12p70, Tumor Necrosis Factor- alpha, Chemokines: Eotaxin-1, Eotaxin-3, Fracktalkine, Interleukin-8, Interferon Gamma-Induced Protein-10, Monocyte Chemotactic Protein-1, Macrophage-Derived Chemokine, Macrophage Inflammatory Protein-1a, Macrophage Inflammatory Protein-1b, Thymus and Activation Regulated Chemokine, Other: Brain Derived Neurotropic Factor |
week 7
|
Cortisol
Time Frame: 7 weeks
|
AM Salivary Cortisol is normally in the range of 100-750 ng/dL.
Higher levels are thought to represent a greater stress response.
|
7 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Eating Behavior
Time Frame: 7 weeks
|
Three Factor Eating Questionnaire will be used to query about eating behavior in different categories using total score: cognitive dietary restraint, disinhibition, and susceptibility to hunger.
Each score is converted to a scaled score from 0 to 100 with the higher score representing more restraint, more dishinibition and less hunger.
|
7 weeks
|
Body Mass Index
Time Frame: 7 weeks
|
Height and weight will be used to calculate Body Mass Index, a ratio of height and weight.
Normal BMI is considered 18.5 to 25.
|
7 weeks
|
Cholesterol
Time Frame: Baseline and week 7
|
serum will be drawn to measure total cholesterol, low density and high density lipoproteins along with Triglycerides.
All are measured in mg/dL.
Normal values include Total Cholesterol <=199, Triglycerides 30 - 149, High Density Lipoprotein 40-59, Low Density Lipoprotein <=129.
|
Baseline and week 7
|
Electrophysiology Mismatch Negativity
Time Frame: Baseline and week 7
|
Mismatch Negativity (MMN) measured in an event related potential paradigm.
The value is expressed in micorvolts and represents the difference in response to standard versus mismatch stimuli measure at 100 milliseconds post stimuli.
The mismatch negativity value varies between 0 and -6 microvolts with greater negative numbers representing greater mismatch negativity.
The MMN is thought primarily to reflect the activity of sensory memory, with, at most, moderate influences of higher-level cognitive processes, such as attention.
|
Baseline and week 7
|
Electrophysiology - Prepulse Inhibition
Time Frame: Baseline and week 7
|
Prepulse Inhibition of the human startle response.
Prepulse Inhibition is expressed as a percentage from 0 to 100 with the higher value presenting greater inhibition.
|
Baseline and week 7
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kristin Cadenhead, MD, University of California, San Diego
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 649467 CMCR Grants Program
- Cadenhead (Other Grant/Funding Number: Krupp Endowed Fund)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early Psychosis
-
National University of Ireland, Galway, IrelandHealth Research Board, Ireland; Health Service Executive, IrelandRecruiting
-
Chinese University of Hong KongIntegrated Community Centers for Mental WellnessActive, not recruitingPsychotic Disorders | Early PsychosisHong Kong
-
Chinese University of Hong KongIntegrated Community Centers for Mental WellnessActive, not recruitingPsychotic Disorders | Early PsychosisHong Kong
-
Temple UniversityCompletedEarly PsychosisUnited States
-
Philipps University Marburg Medical CenterProf. Dr. Andreas Bechdolf (Chair of hospital), Vivantes Hospital Am Urban... and other collaboratorsCompletedEmotional Distress | Delusions | Self Esteem | Early PsychosisGermany
-
University of WashingtonRecruitingCaregiver to a Young Adult With Early PsychosisUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
Universidade do PortoCentro Hospitalar Universitário São João, E.P.E. (CHUSJ); Centro de Investigação... and other collaboratorsNot yet recruitingEarly Childhood, Neurodevelopment | Early Childhood, AnthropometryPortugal
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
Clinical Trials on Cannabidiol oral solution
-
INSYS Therapeutics IncWithdrawn
-
INSYS Therapeutics IncWithdrawn
-
Radius Pharmaceuticals, Inc.TerminatedChildhood Absence EpilepsyUnited States
-
INSYS Therapeutics IncTerminatedSpasms, InfantileUnited States
-
MultiCare Health System Research InstituteNo longer availableRefractory Epilepsy
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedChildhood Absence EpilepsyUnited States
-
Meyer Children's Hospital IRCCSNot yet recruitingEpilepsy | Rare Diseases
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedPrader-Willi SyndromeUnited States
-
INSYS Therapeutics IncCompleted
-
INSYS Therapeutics IncCompleted